Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports

02.05.2024 | Peripheral Vascular Disease (S Kinlay, Section Editor)

Medical Therapy for Peripheral Artery Disease

verfasst von: Mario Enrico Canonico, Connie N. Hess, R. Kevin Rogers, Marc P. Bonaca

Erschienen in: Current Cardiology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Patients with lower extremity peripheral artery disease (PAD) are at high risk for major adverse cardiovascular events (MACE) and major adverse limb events (MALE). This manuscript will review the current evidence for medical therapy in patients with PAD according to different clinical features and the overall cardiovascular (CV) risk.

Recent Findings

The management of PAD encompasses non-pharmacologic strategies, including lifestyle modification such as smoking cessation, supervised exercise, Mediterranean diet and weight loss as well as pharmacologic interventions, particularly for high risk patients. Benefits for reduction of CV and limb outcomes have been demonstrated for new therapies, including antithrombotic therapy (i.e., low-dose rivaroxaban plus aspirin), lipid lowering therapy (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors), and glucose lowering therapy (i.e., sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists). However, the adoption of these therapies in PAD remains suboptimal in practice. Implementation science studies have recently shown promising results in PAD patients.

Summary

Comprehensive medical and non-medical management of PAD patients is crucial to improving patient outcomes, mitigating symptoms, and reducing the risk of MACE and MALE. A personalized approach, considering the patient's overall risk profile and preference, is essential for optimizing medical management of PAD.
Literatur
1.
• Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, et al. Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. Circulation. 2021;144(9). The paper provides updates on the epidemiology and current knowledge in PAD.
2.
•• Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(12). The paper is the latest AHA/ACC LEPAD guidelines.
3.
•• Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816. The paper is the latest ESC PAD guidelines.PubMedCrossRef
4.
Hess CN, Huang Z, Patel MR, Baumgartner I, Berger JS, Blomster JI, et al. Acute Limb Ischemia in Peripheral Artery Disease. Circulation. 2019;140(7):556–65.PubMedCrossRef
5.
Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, et al. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. JAMA Cardiol. 2020.
6.
King RW, Canonico ME, Bonaca MP, Hess CN. Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. J Soc Cardiovasc Angiogr Interv. 2022;1(6):100513.
7.
Berger JS, Abramson BL, Lopes RD, Heizer G, Rockhold FW, Baumgartner I, et al. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vasc Med. 2018;23(6):523–30.PubMedCrossRef
8.
•• Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation. 2018;137(4):338–50. The paper is a subgroup analysis from FOURIER demonstrating the efficacy of evolocumab in PAD patients.PubMedCrossRef
9.
• Narula N, Dannenberg AJ, Olin JW, Bhatt DL, Johnson KW, Nadkarni G, et al. Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia. J Am Coll Cardiol. 2018;72(18):2152–63. The paper highlights the pathophysiology of ALI including the role of thrombo-embolism.PubMedCrossRef
10.
Creager MA, Hamburg NM. Smoking Cessation Improves Outcomes in Patients With Peripheral Artery Disease. JAMA Cardiol. 2022;7(1):15.PubMedCrossRef
11.
Ebbert J, Burke MV, Hays JT. Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence. Patient Prefer Adherence. 2016;435.
12.
López-Laguna N, Martínez-González MA, Toledo E, Babio N, Sorlí JV, Ros E, et al. Risk of peripheral artery disease according to a healthy lifestyle score: The PREDIMED study. Atherosclerosis. 2018;275:133–40.PubMedCrossRef
13.
Treat-Jacobson D, McDermott MM, Beckman JA, Burt MA, Creager MA, Ehrman JK, et al. Implementation of Supervised Exercise Therapy for Patients With Symptomatic Peripheral Artery Disease: A Science Advisory From the American Heart Association. Circulation. 2019;140(13).
14.
Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JAW, Hoffmann WH, et al. Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication. JAMA. 2015;314(18):1936.PubMedCrossRef
15.
Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840–a1840.PubMedPubMedCentralCrossRef
16.
Fowkes FGR, Price JF, Stewart MCW, Butcher I, Leng GC, Pell ACH, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841–8.PubMedCrossRef
17.
•• Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021;42(39):4013–24. The paper is the latest ESC consensus on antithrombotic therapy in PAD, including last evidence after LER.PubMedCrossRef
18.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee Lancet. 1996;348(9038):1329–39.
19.
Canonico ME, Piccolo R, Avvedimento M, Leone A, Esposito S, Franzone A, et al. Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. J Cardiovasc Dev Dis. 2023;10(4):164.PubMedPubMedCentral
20.
Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2008;30(2):192–201.CrossRef
21.
Bonaca MP, Bhatt DL, Storey RF, Steg PhG, Cohen M, Kuder J, et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016;67(23):2719–28.PubMedCrossRef
22.
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309–20.PubMedCrossRef
23.
Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, et al. Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. N Eng J Med. 2007;357(3):217–27.
24.
Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, et al. Vorapaxar in Patients With Peripheral Artery Disease. Circulation. 2013;127(14):1522–9.PubMedCrossRef
25.
Belch JJF, Dormandy J. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825-833.e2.PubMedCrossRef
26.
Tepe G, Bantleon R, Brechtel K, Schmehl J, Zeller T, Claussen CD, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol. 2012;22(9):1998–2006.PubMedCrossRef
27.
Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. The Lancet. 2000;355(9201):346–51.
28.
Moll F, Baumgartner I, Jaff M, Nwachuku C, Tangelder M, Ansel G, et al. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. J Endovasc Ther. 2018;25(2):158–68.PubMedCrossRef
29.
•• Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382(21):1994–2004. The VOYAGER-PAD trial demonstrated the efficacy of DPI in symptomatic LEPAD patients undergoing LER.PubMedCrossRef
30.
Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, et al. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. Circulation. 2020;142(23):2219–30.PubMedCrossRef
31.
Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, et al. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. J Am Coll Cardiol. 2021;78(4):317–26.PubMedCrossRef
32.
Östergren J. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25(1):17–24.PubMedCrossRef
33.
Telmisartan R. or Both in Patients at High Risk for Vascular Events. N Engl J Med. 2008;358(15):1547–59.CrossRef
34.
Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-DeHoff RM, Handberg EM, et al. Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease. Hypertension. 2010;55(1):48–53.PubMedCrossRef
35.
•• Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. The paper is the latest ESC guidelines on dyslipidemia including LDL-C target in ASCVD patients.PubMedCrossRef
36.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360(9326):7–22.
37.
Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645–654.e1.
38.
Kumbhani DJ, Steg PhG, Cannon CP, Eagle KA, Smith SC, Goto S, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864–72.PubMedPubMedCentralCrossRef
39.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–97.PubMedCrossRef
40.
Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6(12):934–43.PubMedCrossRef
41.
Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. J Am Coll Cardiol. 2022;80(14):1366–418.PubMedCrossRef
42.
•• Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, et al. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. J Am Coll Cardiol. 2019;74(9):1167–76. The paper is a subgroup analysis from ODYSSEY OUTCOMES demonstrating the efficacy of alirocumab in PAD patients.PubMedCrossRef
43.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097–107.PubMedCrossRef
44.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.PubMedCrossRef
45.
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med. 2011;365(24):2255–67.
46.
•• Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–140. The paper is the latest ESC guidelines on CVD management in DM patients including the role of SGLT2i and GLP-1RA in ASCVD patients.PubMedCrossRef
47.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359(15):1577–89.PubMedCrossRef
48.
Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, et al. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Circ Cardiovasc Interv. 2019;12(12).
49.
Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, et al. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022;24(7):1288–99.PubMedPubMedCentralCrossRef
50.
Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, et al. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care. 2018;41(10):2229–35.PubMedPubMedCentralCrossRef
51.
• Sillesen H, Debus ES, Enggaard RBB, Frenkel O, Heled Y, Mansor-Lefebvre S, et al. Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease: rationale and design of the STRIDE trial. Eur Heart J. 2021;42(Supplement_1). This paper describes the design of the STRIDE trial investigating the role of GLP-1RA in PAD patients.
52.
Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, et al. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Circulation. 2018;137(4):405–7.PubMedCrossRef
53.
Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of Peripheral Artery Disease. Circ Res. 2021;128(12):1868–84.PubMedCrossRef
54.
Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, et al. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial. Diabetes Obes Metab. 2022;24(6):1072–83.PubMedCrossRef
55.
Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, et al. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020;142(8):734–47.PubMedCrossRef
56.
Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109(7):523–30.PubMedCrossRef
57.
McDermott MM, Criqui MH, Domanchuk K, Ferrucci L, Guralnik JM, Kibbe MR, et al. Cocoa to Improve Walking Performance in Older People With Peripheral Artery Disease. Circ Res. 2020;126(5):589–99.PubMedPubMedCentralCrossRef
58.
Canonico ME, Hsia J, Hess CN, Bonaca MP. Sex differences in guideline-directed medical therapy in 2021–22 among patients with peripheral artery disease. Vasc Med. 2023;1358863X2311553.
59.
Hess CN, Cannon CP, Beckman JA, Goodney PP, Patel MR, Hiatt WR, et al. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2021;77(24):3016–27.PubMedCrossRef
60.
Sonderman M, Aday AW, Farber-Eger E, Mai Q, Freiberg MS, Liebovitz DM, et al. Identifying Patients With Peripheral Artery Disease Using the Electronic Health Record. JACC: Advances. 2023;2(7):100566.
61.
• Hess CN, Nehler M, Daffron A, Morrison J, Buchanan C, Saseen JJ, et al. PRAGMATIC IMPLEMENTATION SCIENCE TO ASSESS LIPID OPTIMIZATION IN PERIPHERAL ARTERY DISEASE: PRIMARY RESULTS OF THE OPTIMIZE PAD-1 TRIAL. J Am Coll Cardiol. 2023;81(8):2105. This abstract includes the preliminary results of the OPTIMIZE PAD-1 trial, an implementation science study of lipid management in PAD patients.CrossRef
Metadaten
Titel
Medical Therapy for Peripheral Artery Disease
verfasst von
Mario Enrico Canonico
Connie N. Hess
R. Kevin Rogers
Marc P. Bonaca
Publikationsdatum
02.05.2024
Verlag
Springer US
Erschienen in
Current Cardiology Reports
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02065-y

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise